Adalimumab Biosimilar on Par With Original in Crohn ' s Disease Adalimumab Biosimilar on Par With Original in Crohn ' s Disease

For patients with moderate to severe active Crohn ' s disease, the adalimumab biosimilar BI 695501 from Boehringer Ingelheim proved as safe and effective as the original, AbbVie ' s Humira, in the phase-3 VOLTAIRE-CD study.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news